<DOC>
	<DOC>NCT00242710</DOC>
	<brief_summary>The purpose of this study is to determine whether bazedoxifene/conjugated estrogens combinations are effective for the prevention of endometrial hyperplasia and for the prevention of osteoporosis in postmenopausal women.</brief_summary>
	<brief_title>Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Endometrial Hyperplasia</mesh_term>
	<mesh_term>Estrogens, Conjugated (USP)</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Bazedoxifene</mesh_term>
	<criteria>Generally healthy, postmenopausal women, aged 40 to less than 65 years Intact uterus At least 12 months of spontaneous amenorrhea, OR 6 months spontaneous amenorrhea with folliclestimulating hormone (FSH) levels &gt; 40 mIU/mL. Use of oral estrogen, progestin, androgen, or SERMcontaining drug products within 8 weeks before screening (12 weeks for the osteoporosis substudy) A history or active presence of clinically important medical disease Malabsorption disorders</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Endometrium</keyword>
	<keyword>Uterus</keyword>
	<keyword>Menopause</keyword>
</DOC>